Xerion is an Australian based specialty pharmaceutical company whose focus is to build a US prescription drug pipeline of 5 new products using AMYCOT® for key dermatological indications. Xerion is currently conducting a $6 million Series A funding round and an IPO is planned in the next 12 months providing early investors a viable exit strategy.
The choice you make above will help our platform display content that is best suited to you
Welcome to the new Wholesale Investor platform. Please use your existing log in details to access the site. Alternatively feel free to use the "Login with LinkedIn" or "Sign in with Google" buttons.
Enter your email to reset your password.